Discovery STREAM

  1. Pragmatic Computational Biology with Andrew Satz 9/20/2023

    This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware?

  2. Nanoassemblr Blaze mRNA Vaccine Demo 4/13/2022

    NxGen Technology delivers a scalable means to perform the critical particle formation step in a nanomedicine development process.

  3. Saudi Arabia Government Leaders Discuss Agile Manufacturing Beyond Borders 10/23/2022

    Learn how government leaders in Saudi Arabia planned for biopharma resilience beyond borders and used agile manufacturing to prepare for the unknown.

  4. Functional Antibody Screening With Abalone Bio's Richard Yu, Ph.D. 7/29/2025

    In this episode of "Better Biopharma," Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening.

  5. Don't Be A D**k With Ochre Bio's Dr. Quin Wills 9/27/2023

    Don't be offended by the title of today's Business of Biotech podcast. Dr. Quin Wills' application of what's become known as "Wheaton's Law" (look it up) is central to the ambitious goals his company, Ochre Bio, is pursuing: pioneering the value of computational biology in large mol discovery and development, putting an end to the global liver disease epidemic, and changing the costly, high-risk approach to clinical trials. On this week's episode, Dr. Wills and I explore how those goals are being addressed despite the challenges they present, and how the company's three guiding principles, don't be a d**k being one of them, align the Ochre team with the mission at hand. 

  6. The NanoAssemblr® Spark™ Robust Low Volume RNA-Lipid Nanoparticle Formulation 4/14/2022

    Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.

  7. Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin 9/7/2023

    Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.”

  8. The NanoAssemblr® Spark™ Instrument Demo 4/13/2022

    The NanoAssemblr® Spark™ uses proprietary microfluidics technology for the controlled and reproducible manufacturing of nanoparticles in small volumes in less than 10 seconds.

  9. Elucidating The Role Of IL-18 In NSCLC Integrated Analysis 1/23/2025

    Hear how imaging mass cytometry, CyTOF, and single-cell sequencing unlock the secrets of the tumor microenvironment. Discover new insights into IL-18 and its impact on non-small cell lung cancer.

  10. Validation Of An LCMS Hybrid Assay With EVOSEP Cleanup 2/17/2025

    By leveraging this innovative combination, the assay achieves detection limits comparable to traditional methodologies while enhancing overall efficiency and reliability.